ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The pSTAT3 levels did not decrease with the TKI treatment, suggesting that STAT3 activation does not depend on BCR::ABL1 activity, and additional genetic alterations may have been involved in CML-BP.